# PharmaMar

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/pharmamar/

## Facts

| Field | Value |
| --- | --- |
| Country | ES |
| Description | company |
| OpenAlex ID | https://openalex.org/F4320327811 |
| ROR ID | https://ror.org/02h694m69 |
| Works | 1,573 |

## Funder papers

- [Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial](https://scholariq.org/papers/niraparib-first-line-maintenance-therapy-in-patients-with-newly-diagnosed/)
- [Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy](https://scholariq.org/papers/small-cell-transformation-in-egfr-mutated-non-small-cell-lung-cancer-dll3/)
- [Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial](https://scholariq.org/papers/efficacy-and-safety-of-niraparib-in-patients-aged-65-years-and-older-with/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.